% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Basset:170085,
      author       = {M. Basset and C. R. Kimmich and N. Schreck$^*$ and J.
                      Krzykalla$^*$ and T. Dittrich and K. Veelken and H.
                      Goldschmidt and A. Seckinger and D. Hose and A. Jauch and C.
                      Müller-Tidow and A. Benner$^*$ and U. Hegenbart and S. O.
                      Schönland},
      title        = {{L}enalidomide and dexamethasone in relapsed/refractory
                      immunoglobulin light chain ({AL}) amyloidosis: results from
                      a large cohort of patients with long follow-up.},
      journal      = {British journal of haematology},
      volume       = {195},
      number       = {2},
      issn         = {1365-2141},
      address      = {Oxford [u.a.]},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2021-01748},
      pages        = {230-243},
      year         = {2021},
      note         = {2021 Oct;195(2):230-243},
      abstract     = {Lenalidomide and dexamethasone (RD) is a standard treatment
                      in relapsed/refractory immunoglobulin light chain (AL)
                      amyloidosis (RRAL). We retrospectively investigated
                      toxicity, efficacy and prognostic markers in 260 patients
                      with RRAL. Patients received a median of two prior treatment
                      lines $(68\%$ had been bortezomib-refractory; $33\%$ had
                      received high-dose melphalan). The median treatment duration
                      was four cycles. The 3-month haematological response rate
                      was $31\%$ [very good haematological response (VGHR) in
                      $18\%].$ The median follow-up was 56·5 months and the
                      median overall survival (OS) and haematological event-free
                      survival (haemEFS) were 32 and 9 months. The 2-year
                      dialysis rate was $15\%.$ VGHR resulted in better OS (62 vs.
                      26 months, P < 0·001). Cardiac progression predicted
                      worse survival (22 vs. 40 months, P = 0·027), although
                      N-terminal prohormone of brain natriuretic peptide
                      (NT-proBNP) increase was frequently observed. Multivariable
                      analysis identified these prognostic factors: NT-proBNP for
                      OS [hazard ratio (HR) 1·71; P < 0·001]; gain 1q21 for
                      haemEFS (HR 1·68, P = 0·014), with a trend for OS (HR
                      1·47, P = 0·084); difference between involved and
                      uninvolved free light chains (dFLC) and light chain isotype
                      for OS (HR 2·22, P < 0·001; HR 1·62, P = 0·016) and
                      haemEFS (HR 1·88, P < 0·001; HR 1·59, P = 0·008).
                      Estimated glomerular filtration rate (HR 0·71,
                      P = 0·004) and 24-h proteinuria (HR 1·10, P = 0·004)
                      were prognostic for renal survival. In conclusion, clonal
                      and organ biomarkers at baseline identify patients with
                      favourable outcome, while VGHR and cardiac progression
                      define prognosis during RD treatment.},
      keywords     = {AL amyloidosis (Other) / biomarkers (Other) / gain 1q21
                      (Other) / lenalidomide (Other) / prognosis (Other)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34341985},
      doi          = {10.1111/bjh.17685},
      url          = {https://inrepo02.dkfz.de/record/170085},
}